Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Trial Profile

Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 Results after 5.7 years of follow up (n=22, data cut off: 30 Jun 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2018 Biomarkers information updated
    • 26 Jul 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top